Belatacept: A New Biologic and Its Role in Kidney Transplantation

Abstract

Spanish

French

OBJECTIVE:

To review the pharmacology, efficacy, safety, and role of belatacept in maintenance immunosuppression in adult kidney transplant recipients (KTR).

DATA SOURCES:

PubMed, EMBASE, International Pharmaceutical Abstracts, Web of Knowledge (1990-November 2011), and Google were searched using the terms belatacept, kidney or renal, and transplant.

STUDY SELECTION AND DATA EXTRACTION:

Relevant articles (English language and human subjects) were reviewed. Selected studies included 3 Phase 2 and 2 Phase 3 trials. Data were compared with Food and Drug Administration (FDA) briefing documents and belatacept full prescribing information.

DATA SYNTHESIS:

Belatacept, a cytotoxic T-lymphocyte–associated antigen 4-immunoglobulin, is the first marketed intravenous maintenance immunosuppressant. It is approved for use in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids to prevent rejection in adult KTR. Belatacept exhibits linear pharmacokinetics and first-order elimination. The less intensive regimen used in Phase 3 trials is approved by the FDA. In low-moderate immunologic risk KTR, short-term patient and allograft survival appear comparable with that seen with cyclosporine, with improved renal function despite more frequent and severe early acute rejection. Preliminary data from Phase 2 corticosteroid-avoidance and conversion trials suggest that better renal function, acceptable rejection rates, and comparable patient and allograft survival may be achieved with belatacept compared with calcineurin inhibitors (CNIs). Common adverse effects of belatacept include anemia, neutropenia, urinary tract infection, headache, and peripheral edema. While a more favorable cardiovascular and metabolic profile and lack of requirement for therapeutic drug monitoring are attractive, a higher frequency of posttransplant lymphoproliferative disorder is concerning. Belatacept drug costs are significantly higher than those of standard CNI- or sirolimus-based regimens.

CONCLUSIONS:

Belatacept provides a new option for maintenance immunosuppression in adult KTR. Further research is needed to compare its efficacy and safety with standard tacrolimus-based regimens, to evaluate whether increased drug costs are offset by long-term improvements in patient and allograft survival, and to establish its role in the immunosuppression armamentarium.

Keywords

belatacept CTLA4-Ig immunosuppression kidney transplantation

Get full access to this article

View all access options for this article.

References

1 Halloran

. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715–29.

2 Meier-Kriesche

Schold

Srinivas

Kaplan

. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378–83.

3 Nankivell

Alexander

. Rejection of the kidney allograft. N Engl J Med 2010;363:1451–62.

4 Snanoudj

Zuber

Legendre

. Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits. Drugs 2010;70:2121–31.

5 Pascual

Theruvath

Kawai

Tolkoff-Rubin

Cosimi

. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002;346:580–90.

Moore

Middleton

Cockwell

Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation 2009;87:591–605.

7Product information. Nulojix (belatacept). Princeton, NJ: Bristol-Myers Squibb, June 2011. www.nulojix.com (accessed 2011 Jul 2).

8Product information. Orenica (abatacept). Princeton, NJ; Bristol-Myers Squibb, August 2009. www.orenica.com (accessed 2011 Jul 2).

Kirk

Harlan

Armstrong

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997;94:8789–94.

10.

Levisetti

Padrid

Szot

Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997;159:5187–91.

11.

11 Linsley

Greene

Brady

Bajorath

Ledbetter

Peach

. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1:793–801.

12.

Larsen

Pearson

Adams

Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005;5:443–53.

13.

13 Shen

Summerill

Shen

Pursley

Kaul

. Safety and pharmacokinetics (PK) of belatacept after a single escalating intravenous (IV) administration in healthy subjects (abstract 102). J Clin Pharmacol 2009;49:1114.

14.

14 Zhou

Shen

Kaul

Pfister

Roy

. Belatacept population pharmacokinetics in renal transplant patients (abstract 1505). Am J Transplant 2010;10(suppl 4):467.

15.

15 Ternant

Paintaud

. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005;5 (suppl 1):S37-47.

16.

16 Shen

Zhou

Townsend

Kaul

. Predictable pharmacokinetics, pharmacodynamics, and exposure-response of belatacept avert the need of therapeutic drug monitoring (abstract 1097). Am J Transplant 2011;11(suppl 2):352.

17.

Durrbach

Pestana

Pearson

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010;10:547–57.

18.

Vincenti

Charpentier

Vanrenterghem

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10:535–46.

19.

Vincenti

Larsen

Durrbach

Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770–81.

20.

Vincenti

Blancho

Durrbach

Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010;21:1587–96.

21.

Ferguson

Grinyo

Vincenti

Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011;11:66–76.

22.

Rostaing

Massari

Garcia

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011;6:430–9.

23.

Grinyo

Nainan

Rial

Renal function at 2 years in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: results from the long-term extension of a phase II study (abstract 226). Am J Transplant 2011;11(suppl 2):99.

24.

Larsen

Grinyo

Medina-Pestana

Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010;90:1528–35.

25.

Medina Pestana

Grinyo

Vanrenterghem

Belatacept compared with cyclosporine in renal allograft recipients of extended criteria donor kidneys: 3-year outcomes from the phase III BENEFIT-EXT trial (abstract 1088). Am J Transplant 2011;11:349.

26.

Vincenti

Larsen

Alberu

Three-year outcomes from BENEFIT: a phase III study of belatacept vs cyclosporine in kidney transplant recipients (abstract 227). Am J Transplant 2011;11:99.

27.

27Cardiovascular and Renal Drugs Advisory Committee meeting. Belatacept injection briefing package. Division of Special Pathogen and Transplant Products Office of Antimicrobial Products Center for Drug Evaluation and Research, FDA. March 1, 2010. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM201858.pdf (accessed 2011 Aug 6).

28.

28Cardiovascular and Renal Drugs Advisory Committee meeting. Addendum belatacept injection briefing package. Division of Special Pathogen and Transplant Products Office of Antimicrobial Products Center for Drug Evaluation and Research, FDA. March 1 2010. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM202327.pdf (accessed 2011 Aug 15).

29.

29 Allen

Preiksaitis

. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009;(suppl 4)9:S87-96.

30.

30 Everly

Bloom

Tsai

Trofe

. Posttransplant lymphoproliferative disorder. Ann Pharmacother 2007;41:1850–8.

31.

Grinyo

Charpentier

Pestana

An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010;90:1521–7.

32.

Haidinger

Hecking

Memarsadeghi

Late onset Pneumocystis pneumonia in renal transplantation after long-term immunosuppression with belatacept. Transpl Infect Dis 2009;11:171–4.

33.

Vanrenterghem

Bresnahan

Campistol

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011;91:976–83.

34.

34 Marshall

Swearingen

. Complexities in transplant revenue management. Prog Transplant 2007;17:94–8.

35.

35Red Book online system [intranet database]. Version 5.1. Greenwood Village, CO: Thomson Reuters (Healthcare), Inc.

36.

McGillicuddy

Kohout

Taber

Clinical and economic analysis of delayed administration of ATG induction in kidney transplantation (abstract 743). Am J Transplant 2011;11:253.

37.

37Medicare Web site. www.medicare.gov/navigation/medicare-basics/medicare-basics-overview.aspx. (accessed 2011 Aug 12).

38.

Tanaka

Kyo

Kokado

Correlation between the Banff 97 classification of renal allograft biopsies and clinical outcome. Transpl Int 2004;17:59–64.

39.

Gaston

Cecka

Kasiske

Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010;90:68–74.

40.

40 Vincenti

Dritselis

Kirkpatrick

. Belatacept. Nat Rev Drug Discov 2011;10:655–6.

41.

Ekberg

Tedesco-Silva

Demirbas

Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562–75.

42.

42 Knoll

Bell

. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999;318:1104–7.

43.

Meier-Kriesche

Gruessner

Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006;6:1111–31.

44.

Fine

Becker

De Geest

Nonadherence consensus conference summary report. Am J Transplant 2009;9:35–41.